ABSTRACT
The widespread use of amphotericin B deoxycholate (DAmB) is limited because of both infusional toxicity and nephrotoxicity. These inherent limitations were the primary motivation to develop lipid formulations of AmB that are safer, but still retain potent antifungal activity. Liposomal amphotericin B consists of true liposomes that are approximately 80 nm in diameter, that contain various lipids and the amphipathic amphotericin B embedded in the wall of the liposome. Liposomal amphotericin B (LAmB) is widely available and has an extensive usage and safety database (Figure 142.1). Structure of LAmB. Redrawn with permission from <xref ref-type="bibr" rid="ref142_138">Stone <italic>et al</italic>. (2016)</xref>. https://s3-euw1-ap-pe-df-pch-content-public-p.s3.eu-west-1.amazonaws.com/9781315152110/08d8042d-9481-4a8d-8c27-9bd589f6de6b/content/fig142_1.tif" xmlns:xlink="https://www.w3.org/1999/xlink"/>
